Last reviewed · How we verify
Single rocuronium dose
Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively inhibits the nicotinic acetylcholine receptor at the neuromuscular junction.
Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively inhibits the nicotinic acetylcholine receptor at the neuromuscular junction. Used for Endotracheal intubation and/or surgical muscle relaxation.
At a glance
| Generic name | Single rocuronium dose |
|---|---|
| Sponsor | University Hospital, Antwerp |
| Drug class | Non-depolarizing neuromuscular blocking agent |
| Target | Nicotinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 3 |
Mechanism of action
This inhibition prevents acetylcholine from binding to the receptor, leading to muscle paralysis. The effect is reversible with anticholinesterases or by allowing time for spontaneous recovery.
Approved indications
- Endotracheal intubation and/or surgical muscle relaxation
Common side effects
- Hypotension
- Bradycardia
- Respiratory depression
Key clinical trials
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Changes of Ciprofol Dosage and Bispectral Index Required for Loss of Consciousness in Patients of Different Ages
- TetraGraph to Evaluate Onset and Recovery Times of Rocuronium (NA)
- Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery (NA)
- Oliceridine Dose for Tracheal Intubation Hemodynamic Elevation: Up-and-Down Trial (NA)
- Perioperative GDNF as a Predictive Factor for Postoperative Delirium and Adverse Neurological Outcomes in Pediatric Surgery (NA)
- Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery (PHASE4)
- Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Single rocuronium dose CI brief — competitive landscape report
- Single rocuronium dose updates RSS · CI watch RSS
- University Hospital, Antwerp portfolio CI